NoblePeak Vision Corp. Offers Patented Technology to Integrate Germanium Photodetectors With Silicon Circuits at the November 5, 2010 Sealed Bid Sale

WELLESLEY HILLS, Massachusetts, October 4, 2010 - Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that he is offering
for sale the patented technology to integrate germanium photodetectors with
silicon circuits at the November 5, 2010 sealed bid sale of NoblePeak Vision
Corp. assets.

NoblePeak has developed and implemented a process flow that incorporates
single crystal germanium photodetectors with CMOS circuits. Germanium
detectors allow the detection of a much wider spectrum of light than silicon
imagers. By forming an array of such detectors and combining them with
on-chip imaging circuitry, visible-to-short wave infrared imagers have been
fabricated at high volume with silicon economics.

Germanium is a suitable material for photodetectors. Germanium is
invariably used as a relatively dilute SiGe alloy (<30% Ge) in very thin
layers. NoblePeak developed a special growth technique which circumnavigates
the difficulties of growing thick pure layers of germanium.

The intellectual property, fixed assets and inventory will be sold by a
sealed bid sale at 12:00 noon on November 5, 2010.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's Office - jffinnjr@finnwarnkegayton.com
or +1-781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm Finn, Warnke &
Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as assignee for
the benefit of creditors and liquidating agent for a corporation. He has been
involved in a number of loan workouts and bankruptcy cases for thirty-five
(35) years. His most recent Assignments for the Benefit of Creditors in the
biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect
Therapeutics, Inc. and Epix Pharmaceuticals, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegayton.com.

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, jffinnjr at finnwarnkegayton.com